Lv7
5000 积分 2022-08-11 加入
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
10天前
已完结
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
18天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
2个月前
已完结
LBA14 First-in-human phase I study of GTA182, a novel MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted advanced non-small cell lung cancer
2个月前
已关闭
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
3个月前
已完结
OA08.01 BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007
3个月前
已关闭
P3.18.71 CA240-0007: BMS-986504 With Anti-PD-1 or Chemotherapy as Treatment for Advanced Solid Tumors With Homozygous MTAP Deletion
3个月前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
3个月前
已完结
How AI agents will change research: a scientist’s guide
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4个月前
已完结
皖公网安备34019202002308
